Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Follow-On Biologics: Defeat For Waxman, Win For Health Reform

This article was originally published in The Pink Sheet Daily

Executive Summary

Lopsided committee vote suggests that lengthy exclusivity is here to stay, which means that big pharma can get more comfortably behind the broader reform effort.

You may also be interested in...

Rep. Pallone’s Energy And Commerce Win Is Salve For Generics

Anna Eshoo, who championed the brand-friendly biosimilars pathway, had challenged Pallone for ranking member post in House Energy and Commerce Committee.

Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents

Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.

How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique

Pennsylvania Republican Joe Pitts, chairman of the House Energy and Commerce Health Subcommittee, has a straightforward approach to reauthorizing the Prescription Drug User Fee Act – get it done early.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts